Evidence map›Paper›PMID 40984773›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2026

Innate Immune-Cloaked Microgel-Coated Mesenchymal Stromal Cells Reverse Persistent Pulmonary Fibrosis via Reparative Macrophages.

Ik Sung Cho, Amal Yaghmour, Akshay Joshi, Prerak Gupta, Mark A Sanborn, Maria Paula Zappia, Sing Wan Wong, Gang Cheng, Maxim V Frolov, Jalees Rehman and 1 more

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ik Sung ChoDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Amal YaghmourDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Akshay JoshiDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Prerak GuptaDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Mark A SanbornDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Maria Paula ZappiaDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Sing Wan WongDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.
Gang ChengDepartment of Chemical Engineering, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Maxim V FrolovDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Jalees RehmanDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, 60607, USA.
Jae-Won ShinDepartment of Pharmacology and Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.ORCID 0000-0003-4823-6373

Funding

TRAINING PROGRAM IN LUNG BIOLOGY AND PATHOBIOLOGYT32HL007829 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DOLLY MEHTA · 1995 to 2026
$15.6M
Synthetic Biology and Optogenetics CoreP01HL151327 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MO, GARY CH · 2021 to 2025
$11.8M
Amplification Mechanisms of Lung Endothelial Inflammation During Acute Lung InjuryR01HL152515 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI REHMAN, JALEES · 2021 to 2024
$2.3M
Encapsulation of mesenchymal stromal cells in engineered microgels for resolution of lung fibrosisR01HL141255 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHIN, JAE-WON · 2019 to 2023
$2.0M
Engineering microscale hydrogel deposition to direct single stem cell differentiationR01GM141147 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHIN, JAE-WON · 2021 to 2024
$1.9M
Therapeutic nanoscale matrimeresR01EB034507 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHIN, JAE-WON · 2023 to 2025
$1.3M
Engineering extracellular vesicles for therapeutic receptor activationR01HL171590 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kostandin Pajcini, Jae-Won Shin · 2024 to 2026
$1.1M
Engineering mesenchymal stromal cells to treat muscle fibrosisK99AR079561 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI WONG, SING-WAN · 2021 to 2022
$197k
American Heart Association 24POST1194264American Heart Association 24POST1241463American Heart Association 916834National Science Foundation, Division of Chemical, Bioengineering, Environmental, and Transport Systems 2143857NHLBI NIH HHS P01 HL151327NHLBI NIH HHS P01-HL151327NHLBI NIH HHS R01 HL141255NHLBI NIH HHS R01-HL141255NHLBI NIH HHS R01 HL152515NHLBI NIH HHS R01-HL152515NHLBI NIH HHS R01 HL171590NHLBI NIH HHS R01-HL171590NHLBI NIH HHS T32 HL007829NHLBI NIH HHS T32-HL007829NIAMS NIH HHS K99 AR079561NIAMS NIH HHS K99AR079561NIBIB NIH HHS R01 EB034507NIBIB NIH HHS R01-EB034507NIGMS NIH HHS R01 GM141147NIGMS NIH HHS R01-GM141147
6 · The paper itself

Abstract

The innate immune system plays a dual role in both mediating pathogenic processes following tissue damage and acting as a barrier to effective therapeutic delivery. Strategies that evade immune clearance while modulating host immune components offer promising solutions for treating complex chronic diseases, such as fibrosis. Here, an innate immune checkpoint material-based strategy is presented in which mesenchymal stromal cells, coated with a soft conformal microgel and functionalized with the CD47 self-marker agonist, effectively evade clearance by tissue resident macrophages. These engineered cells reverse persistent fibrotic damage in the lungs through a paracrine mechanism. Single-cell RNA sequencing identifies a transitional antigen-presenting macrophage subpopulation that mediates these reparative effects. By combining immune cloaking with the presentation of local signals encoded in the gel coatings, this strategy can be used to design secretory cells for long-term tissue remodeling, enabling a living pharmacy for chronic tissue damage.

Indexed as

Immunity, InnateMacrophagesMesenchymal Stem CellsPulmonary FibrosisAnimalsCD47 AntigenGelsHumansMiceMice, Inbred C57BLCD47 AntigenGelsbiomaterialsfibrosisimmune cloakingliving pharmacysingle cell encapsulation

Identifiers

PMID40984773
PMCPMC13000953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.